Brief: Bridgebio Submits NDA To FDA For Bbp-418 For Individuals Living With Lgmd2i/R9
30/03/2026 12:59
March 30 (Reuters) - BridgeBio Pharma Inc BBIO.O: BRIDGEBIO SUBMITS NDA TO FDA FOR BBP-418 FOR INDIVIDUALS LIVING WITH LGMD2I/R9 BRIDGEBIO PHARMA INC - ANTICIPATES U.S. LAUNCH OF BBP-418 IN LATE 2026/EARLY 2027 BRIDGEBIO PHARMA INC - IF APPROVED, BRIDGEBIO MAY QUALIFY FOR PRIORITY REVIEW VOUCHER Source text: ID:nGNX4lKpCX Further company coverage: BBIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels